ReviewFrontiers in endocrinology2018
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas.
Review in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas.Redox biology · 2026Article
- Magnetic resonance imaging-based morphometric differences in the normal pituitary gland with functional and nonfunctional pituitary adenomas.Surgical neurology international · 2026Article
- MicroRNA networks in prolactinoma tumorigenesis: a scoping review.Cancer cell international · 2024Article
- L-Dopa Might Be Insufficient to Suppress Development of Prolactinomas in Dihydropteridine Reductase-Deficiency Patients.JCEM case reports · 2024Article
- Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects.Life (Basel, Switzerland) · 2023Review
- Article
- A giant invasive macroprolactinoma with recurrent nasal bleeding as the first clinical presentation: case report and review of literature.BMC endocrine disorders · 2023Review
- Current and Perspective Approaches to the Treatment of Prolactinomas.Acta medica Lituanic · 2023Review
- Cabergoline Failure and a Spontaneous Pregnancy in a Microprolactinoma with High Prolactin Levels.Journal of personalized medicine · 2022Article
- Clinical Biology of the Pituitary Adenoma.Endocrine reviews · 2022Review
- The dopaminergic control of Cushing's syndrome.Journal of endocrinological investigation · 2022Review
- Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, Predictors and Management: A Case Report and Literature Review.Journal of clinical medicine · 2022Review
- A New Method for the Visualization of Living Dopaminergic Neurons and Prospects for Using It to Develop Targeted Drug Delivery to These Cells.International journal of molecular sciences · 2022Article
- Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?Frontiers in endocrinology · 2022Review
- A success targeted nano delivery to lung cancer cells with multi-walled carbon nanotubes conjugated to bromocriptine.Scientific reports · 2021Article
- Endocrinopathies and Male Infertility.Life (Basel, Switzerland) · 2021Review
- The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.BMC endocrine disorders · 2021Article
- Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.Frontiers in endocrinology · 2021Article
- Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review.Frontiers in oncology · 2021Review
- Inhibition of lncRNA-UCA1 suppresses pituitary cancer cell growth and prolactin (PRL) secretion via attenuating glycolysis pathway.In vitro cellular & developmental biology. Animal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions. The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.